Yongsheng Zhang1, Liangsheng Guo2, Pengfei Xing3, Yuanyuan Chen3, Feng Li1, Weipei Zhu2, Xueguan Lu3. 1. Department of Pathology, The Second Affiliated Hospital of Soochow University Suzhou, China. 2. Department of Gynecology, The Second Affiliated Hospital of Soochow University Suzhou, China. 3. Department of Oncology & Radiotherapy, The Second Affiliated Hospital of Soochow University Suzhou, China.
Abstract
PURPOSE: To investigate the expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) in specimens from cases of normal cervical epithelium (NCE), cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC), and to evaluate whether there is evidence implicating oncogene-induced senescence (OIS) in cervical squamous cell cancer development. METHODS: The immunohistochemical expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were investigated in formalin-fixed paraffin-embedded specimens from 19 NCE, 51 CIN and 21 SCC cases, respectively. Comparisons among different groups for each marker were performed with Chi-square test. RESULTS: The expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were significantly higher in both CIN and SCC compared to NCE. Furthermore, the expression of p15(INK4b) and p21(Waf1/Cip1) was significantly higher in CIN П compared to CIN І, and these expressions were statistically higher in CIN Ш compared to CIN П, respectively. The p16(INK4a) expression was significantly higher in CIN Ш compared to CIN І. CONCLUSIONS: The results suggested that the senescence programs mediated by p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were activated during the stage of CIN and SCC, and demonstrated that senescence may play important role in preventing from NCE to SCC.
PURPOSE: To investigate the expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) in specimens from cases of normal cervical epithelium (NCE), cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC), and to evaluate whether there is evidence implicating oncogene-induced senescence (OIS) in cervical squamous cell cancer development. METHODS: The immunohistochemical expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were investigated in formalin-fixed paraffin-embedded specimens from 19 NCE, 51 CIN and 21 SCC cases, respectively. Comparisons among different groups for each marker were performed with Chi-square test. RESULTS: The expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were significantly higher in both CIN and SCC compared to NCE. Furthermore, the expression of p15(INK4b) and p21(Waf1/Cip1) was significantly higher in CIN П compared to CIN І, and these expressions were statistically higher in CIN Ш compared to CIN П, respectively. The p16(INK4a) expression was significantly higher in CIN Ш compared to CIN І. CONCLUSIONS: The results suggested that the senescence programs mediated by p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were activated during the stage of CIN and SCC, and demonstrated that senescence may play important role in preventing from NCE to SCC.
Authors: M E Caldwell; G M DeNicola; C P Martins; M A Jacobetz; A Maitra; R H Hruban; D A Tuveson Journal: Oncogene Date: 2011-08-22 Impact factor: 9.867
Authors: G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith Journal: Proc Natl Acad Sci U S A Date: 1995-09-26 Impact factor: 11.205
Authors: Peng Bai; Xue Xiao; Juan Zou; Lin Cui; Tri M Bui Nguyen; Jinsong Liu; Jianguo Xiao; Bin Chang; Jin Wu; He Wang Journal: Exp Ther Med Date: 2012-03-22 Impact factor: 2.447
Authors: Manuel Collado; Jesús Gil; Alejo Efeyan; Carmen Guerra; Alberto J Schuhmacher; Marta Barradas; Alberto Benguría; Angel Zaballos; Juana M Flores; Mariano Barbacid; David Beach; Manuel Serrano Journal: Nature Date: 2005-08-04 Impact factor: 49.962
Authors: S Forbes; J Clements; E Dawson; S Bamford; T Webb; A Dogan; A Flanagan; J Teague; R Wooster; P A Futreal; M R Stratton Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640
Authors: Steven F Gameiro; Bart Kolendowski; Ali Zhang; John W Barrett; Anthony C Nichols; Joe Torchia; Joe S Mymryk Journal: Oncotarget Date: 2017-08-03